At enrollment and repeating again at two 4-week intervals, whole blood from PD patients and controls will be obtained percutaneously using standard sterile techniques. CBC with WBC differential, FACS analysis for T cell markers, and Treg functional assays will be performed and used to calculate immune response profiles as a baseline for comparison after drug treatment. Blood chemistries will be analyzed including liver enzymes, electrolytes, blood urea nitrogen, creatinine, total protein, albumin and bilirubin levels, and anti-GM-CSF antibodies will be assessed in PD patients. PD patients will be evaluated by physical and clinical examinations, including UPDRS part III assessments for evaluation of motor function.